The prognostic implications of the IMP3-PDPN axis as therapeutic targets against OSCC with bone invasion are proposed.
Dual expression of IMP3 and PDPN but not the single expression of either IMP3 or PDPN was associated with bone invasion in patients with OSCC.
IMP3 or PDPN depletion inhibited the invasive capacity of OSCC cells in vitro, tumorigenesis and regional bone destruction in vivo.
IMP3 and PDPN may have strong influence on OSCC pathogenesis, especially in bone invasion of OSCC.